Literature DB >> 23728604

Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication.

Christina Mangurian1, Funmi Giwa, Martha Shumway, Elena Fuentes-Afflick, Eliseo J Pérez-Stable, James W Dilley, Dean Schillinger.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate attitudes of primary care providers toward barriers to metabolic monitoring and to characterize their beliefs about providers' responsibility for monitoring and reducing cardiovascular risk for people with severe mental illness.
METHODS: An anonymous survey was administered to 214 primary care providers working in 23 public community health clinics in San Francisco.
RESULTS: The response rate was 77% (164 of 214). Nearly 40% of primary care providers were unaware of consensus guidelines for metabolic monitoring of people who take second-generation antipsychotic medications. Responses showed variation in providers' beliefs about who should monitor patients' metabolic risk. The major barriers to metabolic monitoring were severity of psychiatric illness, difficulty collaborating with psychiatrists, and difficulty arranging psychiatric follow-up.
CONCLUSIONS: Primary care providers believed that better communication between primary care providers and psychiatrists would facilitate metabolic monitoring and promote better treatment for patients with severe mental illness who are taking antipsychotic medications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728604      PMCID: PMC3780562          DOI: 10.1176/appi.ps.002542012

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  15 in total

Review 1.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

2.  Twenty-five year mortality of a community cohort with schizophrenia.

Authors:  Steve Brown; Miranda Kim; Clemence Mitchell; Hazel Inskip
Journal:  Br J Psychiatry       Date:  2010-02       Impact factor: 9.319

3.  Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

Authors:  Peter F Buckley; Del D Miller; Beth Singer; John Arena; Edna M Stirewalt
Journal:  Schizophr Res       Date:  2005-06-20       Impact factor: 4.939

4.  Psychiatric opinion and antipsychotic selection in the management of schizophrenia.

Authors:  Melissa R Arbuckle; Marc J Gameroff; Steven C Marcus; Joyce C West; Joshua Wilk; Mark Olfson
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

5.  Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

Authors:  Joseph P McEvoy; Jonathan M Meyer; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Lisa Sullivan; Herbert Y Meltzer; John Hsiao; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-08-30       Impact factor: 4.939

Review 6.  The medical home model: new opportunities for psychiatric services in the United States.

Authors:  Jonathan M Amiel; Harold Alan Pincus
Journal:  Curr Opin Psychiatry       Date:  2011-11       Impact factor: 4.741

7.  Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists.

Authors:  S G Parameswaran; C Chang; A K Swenson; M Shumway; M Olfson; C V Mangurian
Journal:  Schizophr Res       Date:  2012-12-09       Impact factor: 4.939

8.  Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.

Authors:  Elaine H Morrato; Brian Cuffel; John W Newcomer; Ilise Lombardo; Siddhesh Kamat; John Barron
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

9.  Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state.

Authors:  Susan M Essock; Nancy H Covell; Emily Leckman-Westin; Jeffrey A Lieberman; Lloyd I Sederer; Edith Kealey; Molly T Finnerty
Journal:  Psychiatr Serv       Date:  2009-12       Impact factor: 3.084

10.  Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Authors:  Elaine H Morrato; Benjamin Druss; Daniel M Hartung; Robert J Valuck; Richard Allen; Elizabeth Campagna; John W Newcomer
Journal:  Arch Gen Psychiatry       Date:  2010-01
View more
  15 in total

1.  Opinions of Primary Care Clinicians and Psychiatrists on Monitoring the Metabolic Effects of Antipsychotics.

Authors:  Christina Mangurian; Aishat Giwa; Erin Brosey; Martha Shumway; James Dilley; Elena Fuentes-Afflick; Eliseo J Pérez-Stable; Dean Schillinger
Journal:  J Am Board Fam Med       Date:  2019 May-Jun       Impact factor: 2.657

Review 2.  Physical Health and Drug Safety in Individuals with Schizophrenia.

Authors:  Tamara Pringsheim; Martina Kelly; Doug Urness; Michael Teehan; Zahinoor Ismail; David Gardner
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

3.  A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists.

Authors:  Christina Mangurian; Chelsea Modlin; Lindsey Williams; Susan Essock; Nicholas S Riano; Martha Shumway; John W Newcomer; James W Dilley; Dean Schillinger
Journal:  Community Ment Health J       Date:  2017-11-28

Review 4.  Serious mental illness and the role of primary care.

Authors:  Claire Planner; Linda Gask; Siobhan Reilly
Journal:  Curr Psychiatry Rep       Date:  2014-08       Impact factor: 5.285

5.  Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study.

Authors:  Christina Mangurian; Dean Schillinger; John W Newcomer; Eric Vittinghoff; Susan Essock; Zheng Zhu; Wendy Dyer; Julie Schmittdiel
Journal:  J Gen Intern Med       Date:  2017-10-31       Impact factor: 5.128

6.  Evaluating the safety of mental health-related prescribing in UK primary care: a cross-sectional study using the Clinical Practice Research Datalink (CPRD).

Authors:  Wael Y Khawagi; Douglas Steinke; Matthew J Carr; Alison K Wright; Darren M Ashcroft; Anthony Avery; Richard Neil Keers
Journal:  BMJ Qual Saf       Date:  2021-08-25       Impact factor: 7.418

Review 7.  Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review.

Authors:  Christina Mangurian; John W Newcomer; Chelsea Modlin; Dean Schillinger
Journal:  J Gen Intern Med       Date:  2016-05-05       Impact factor: 5.128

8.  Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study - a cross-sectional study.

Authors:  Jennifer Fontaine; Evelyn Chin; Jean-François Provencher; Anthony Rainone; Dana Wazzan; Carmella Roy; Soham Rej; Marie Lordkipanidze; Vincent Dagenais-Beaulé
Journal:  BMJ Open       Date:  2022-04-12       Impact factor: 2.692

9.  Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada.

Authors:  Diane H Fredrikson; Heidi N Boyda; Lurdes Tse; Zachary Whitney; Mark A Pattison; Fred J Ott; Laura Hansen; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2014-09-05       Impact factor: 4.157

10.  The effectiveness of specialist roles in mental health metabolic monitoring: a retrospective cross-sectional comparison study.

Authors:  Brian McKenna; Trentham Furness; Elizabeth Wallace; Brenda Happell; Robert Stanton; Chris Platania-Phung; Karen-leigh Edward; David Castle
Journal:  BMC Psychiatry       Date:  2014-09-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.